Foamy virus, an original retroviral model;Les virus foamy, un modèle rétroviral original

Virologie

Volumn 10, Issue 6, 2006, Pages 443-454

  Lehmann Che, J ^a   Renault, N ^a   Giron, M L ^a   Saib A ^a  

^a CNRS   (France)

Author keywords

Complex retrovirus; Foamy virus; Spumavirus

Indexed keywords

HEPATITIS B VIRUS; NONHUMAN; PREVALENCE; RETROPOSON; RETROVIRUS; REVIEW; SPUMA VIRUS; VIRUS INFECTION; VIRUS ISOLATION; VIRUS REPLICATION; VIRUS TRANSMISSION; YEAST;

BOS; EQUIDAE; HEPATITIS B VIRUS; HUMAN SPUMARETROVIRUS; MAMMALIA; PRIMATES; SIMIAE; SPUMAVIRUS;

EID: 33847295730     PISSN: 12678694     EISSN: None     Source Type: Journal    
DOI: 10.1684/vir.2006.0038     Document Type: Review

References (115)

1. Enders JF, Peebles TC. Propagation in tissue cultures of cytopathogenic agents from patients with measles. Proc Soc Exp Biol Med 1954 ; 86 : 277-86.
2. Riggs JL, et al. Syncytium-forming agent isolated from domestic cats. Nature 1969 ; 222 : 1190-1.
3. Johnson RH, Oginnusi AA, Ladds PW. Isolations and serology of bovine spumavirus. Aust Vet J 1983 ; 60 : 147.
4. Tobaly-Tapiero J, et al. Isolation and characterization of an equine foamy virus. J Virol 2000 ; 74 : 4064-73.
5. Falcone V, Schweizer M, Neumann-Haefelin D. Replication of primate foamy viruses in natural and experimental hosts. Curr Top Microbiol Immunol 2003 ; 277 : 161-80.
6. Falcone V, et al. Sites of simian foamy virus persistence in naturally infected African green monkeys : latent provirus is ubiquitous, whereas viral replication is restricted to the oral mucosa. Virology 1999 ; 257 : 7-14.
7. Calattini S, et al. Modes of transmission and genetic diversity of foamy viruses in a Macaca tonkeana colony. Retrovirology 2006 ; 3 : 23.
8. Broussard SR, et al. Characterization of new simian foamy viruses from African nonhuman primates. Virology 1997 ; 237 : 349-59.
9. Cummins JE, et al. Mucosal and systemic antibody responses in humans infected with simian foamy virus. J Virol 2005 ; 79 : 13186-9.
10. Achong BG, et al. An unusual virus in cultures from a human nasopharyngeal carcinoma. J Natl Cancer Inst 1971 ; 46 : 299-307.
11. Achong BG, Mansell PW, Epstein MA. A new human virus in cultures from a nasopharyngeal carcinoma. J Pathol 1971 ; 103 : 18.
12. Herchenroder O, et al. Isolation, cloning, and sequencing of simian foamy viruses from chimpanzees (SFVcpz) : high homology to human foamy virus (HFV). Virology 1994 ; 201 : 187-99.
13. Schweizer M, et al. Simian foamy virus isolated from an accidentally infected human individual. J Virol 1997 ; 71 : 4821-4.
14. Jones-Engel L, et al. Primate-to-human retroviral transmission in Asia. Emerg Infect Dis 2005 ; 11 : 1028-35.
15. Heneine W, et al. Identification of a human population infected with simian foamy viruses. Nat Med 1998 ; 4 : 403-7.
16. Sandstrom PA, et al. Simian foamy virus infection among zoo keepers. Lancet 2000 ; 355 : 551-2.
17. Heneine W, et al. Human infection with foamy viruses. Curr Top Microbiol Immunol 2003 ; 277 : 181-96.
18. Lori F, et al. Viral DNA carried by human immunodeficiency virus type 1 virions. J Virol 1992 ; 66 : 5067-74.
19. Trono D. Partial reverse transcripts in virions from human immunodeficiency and murine leukemia viruses. J Virol 1992 ; 66 : 4893-900.
20. Delelis O, Saib A, Sonigo P. Biphasic DNA synthesis in spumaviruses. J Virol 2003 ; 77 : 8141-6.
21. Yu SF, et al. Human foamy virus replication : a pathway distinct from that of retroviruses and hepadnaviruses. Science 1996 ; 271 : 1579-82.
22. Moebes A, et al. Human foamy virus reverse transcription that occurs late in the viral replication cycle. J Virol 1997 ; 71 : 7305-11.
23. Yu SF, Sullivan MD, Linial ML. Evidence that the human foamy virus genome is DNA. J Virol 1999 ; 73 : 1565-72.
24. Sandmeyer SB. Yeast retrotransposons. Curr Opin Genet Dev 1992 ; 2 : 705-11.
25. Heidmann T, Heidmann O, Nicolas JF. An indicator gene to demonstrate intracellular transposition of defective retroviruses. Proc Natl Acad Sci USA 1988 ; 85 : 2219-23.
26. Heidmann O, Heidmann T. Retrotransposition of a mouse IAP sequence tagged with an indicator gene. Cell 1991 ; 64 : 159-70.
27. Heinkelein M, et al. Efficient intracellular retrotransposition of an exogenous primate retrovirus genome. EMBO J 2000 ; 19 : 3436-45.
28. Cullen BR. Mechanism of action of regulatory proteins encoded by complex retroviruses. Microbiol Rev 1992 ; 56 : 375-94.
29. Baunach G, et al. Functional analysis of human foamy virus accessory reading frames. J Virol 1993 ; 67 : 5411-8.
30. Lochelt M, Muranyi W, Flugel RM. Human foamy virus genome possesses an internal, Bel-1-dependent and functional promoter. Proc Natl Acad Sci USA 1993 ; 90 : 7317-21.
31. Lochelt M, Flugel RM, Aboud M. The human foamy virus internal promoter directs the expression of the functional Bel 1 transactivator and Bet protein early after infection. J Virol 1994 ; 68 : 638-45.
32. Pfrepper KI, et al. Molecular characterization of proteolytic processing of the Gag proteins of human spumavirus. J Virol 1999 ; 73 : 7907-11.
33. Enssle J, et al. Carboxy-terminal cleavage of the human foamy virus Gag precursor molecule is an essential step in the viral life cycle. J Virol 1997 ; 71 : 7312-7.
34. Zemba M, et al. The carboxy-terminal p3Gag domain of the human foamy virus Gag precursor is required for efficient virus infectivity. Virology 1998 ; 247 : 7-13.
35. Merkulov GV, et al. A critical proteolytic cleavage site near the C terminus of the yeast retrotransposon Ty1 Gag protein. J Virol 1996 ; 70 : 5548-56.
36. Tobaly-Tapiero J, et al. Human foamy virus capsid formation requires an interaction domain in the N terminus of Gag. J Virol 2001 ; 75 : 4367-75.
37. Eastman SW, Linial ML. Identification of a conserved residue of foamy virus Gag required for intracellular capsid assembly. J Virol 2001 ; 75 : 6857-64.
38. Choi G, et al. Identification of a cytoplasmic targeting/retention signal in a retroviral Gag polyprotein. J Virol 1999 ; 73 : 5431-7.
39. Enssle J, et al. Foamy virus reverse transcriptase is expressed independently from the Gag protein. Proc Natl Acad Sci USA 1996 ; 93 : 4137-41.
40. Jordan I, et al. Expression of human foamy virus reverse transcriptase involves a spliced pol mRNA. Virology 1996 ; 224 : 314-9.
41. Lochelt M, Flugel RM. The human foamy virus pol gene is expressed as a Pro-Pol polyprotein and not as a Gag-Pol fusion protein. J Virol 1996 ; 70 : 1033-40.
42. Pfrepper KI, et al. Molecular characterization of proteolytic processing of the Pol proteins of human foamy virus reveals novel features of the viral protease. J Virol 1998 ; 72 : 7648-52.
43. Lindemann D, et al. A particle-associated glycoprotein signal peptide essential for virus maturation and infectivity. J Virol 2001 ; 75 : 5762-71.
44. Petit C, et al. Targeting of incoming retroviral Gag to the centrosome involves a direct interaction with the dynein light chain 8. J Cell Sci 2003 ; 116(Pt 16) : 3433-42.
45. Saib A, et al. Nuclear targeting of incoming human foamy virus Gag proteins involves a centriolar step. J Virol 1997 ; 71 : 1155-61.
46. Giron ML, et al. Expression and maturation of human foamy virus Gag precursor polypeptides. J Virol 1997 ; 71 : 1635-9.
47. Lehmann-Che J, et al. Protease-dependent uncoating of a complex retrovirus. J Virol 2005 ; 79 : 9244-53.
48. Rumlova M, et al. Specific in vitro cleavage of Mason-Pfizer monkey virus capsid protein : evidence for a potential role of retroviral protease in early stages of infection. Virology 2003 ; 310 : 310-8.
49. Nagy K, et al. Antiviral activity of human immunodeficiency virus type 1 protease inhibitors in a single cycle of infection : evidence for a role of protease in the early phase. J Virol 1994 ; 68 : 757-65.
50. Bieniasz PD, Weiss RA, McClure MO. Cell cycle dependence of foamy retrovirus infection. J Virol 1995 ; 69 : 7295-9.
51. Trobridge G, Russell DW. Cell cycle requirements for transduction by foamy virus vectors compared to those of oncovirus and lentivirus vectors. J Virol 2004 ; 78 : 2327-35.
52. Roe T, et al. Integration of murine leukemia virus DNA depends on mitosis. EMBO J 1993 ; 12 : 2099-108.
53. Lewis P, Hensel M, Emerman M. Human immunodeficiency virus infection of cells arrested in the cell cycle. EMBO J 1992 ; 11 : 3053-8.
54. Jarrosson-Wuilleme L, et al. Transduction of nondividing human macrophages with gammaretrovirus-derived vectors. J Virol 2006 ; 80 : 1152-9.
55. Nisole S, Stoye JP, Saib A. TRIM family proteins : retroviral restriction and antiviral defence. Nat Rev Microbiol 2005 ; 3 : 799-808.
56. Bhagwat AS. DNA-cytosine deaminases : from antibody maturation to antiviral defense. DNA Repair (Amst) 2004 ; 3 : 85-9.
57. Saumet A, Lecellier CH. Anti-viral RNA silencing : do we look like plants? Retrovirology 2006 ; 3 : 3.
58. Mangeat B, et al. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 2003 ; 424 : 99-103.
59. Harris RS, et al. DNA deamination mediates innate immunity to retroviral infection. Cell 2003 ; 113 : 803-9.
60. Stopak K, et al. HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol Cell 2003 ; 12 : 591-601.
61. Marin M, et al. HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nat Med 2003 ; 9 : 1398-403.
62. Mehle A, et al. Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway. J Biol Chem 2004 ; 279 : 7792-8.
63. Sheehy AM, Gaddis NC, Malim MH. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat Med 2003 ; 9 : 1404-7.
64. Navarro F, et al. Complementary function of the two catalytic domains of APOBEC3G. Virology 2005 ; 333 : 374-86.
65. Dutko JA, et al. Inhibition of a yeast LTR retrotransposon by human APOBEC3 cytidine deaminases. Curr Biol 2005 ; 15 : 661-6.
66. Esnault C, et al. APOBEC3G cytidine deaminase inhibits retrotransposition of endogenous retroviruses. Nature 2005 ; 433 : 430-3.
67. Noguchi C, et al. G to A hypermutation of hepatitis B virus. Hepatology 2005 ; 4 : 626-33.
68. Russell RA, et al. Foamy virus Bet proteins function as novel inhibitors of the APOBEC3 family of innate antiretroviral defense factors. J Virol 2005 ; 79 : 8724-31.
69. Delebecque F, et al. Restriction of Foamy Viruses by APOBEC cytidine deaminases. J Virol 2006 ; 80 : 605-14.
70. Lochelt M, et al. The antiretroviral activity of APOBEC3 is inhibited by the foamy virus accessory Bet protein. Proc Natl Acad Sci USA 2005 ; 102 : 7982-7.
71. Strebel K. APOBEC3G & HTLV1 : inhibition without deamination. Retrovirology 2005 ; 2 : 37.
72. Bernstein E, et al. Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature 2001 ; 409 : 363-6.
73. Hamilton AJ, Baulcombe DC. A species of small antisense RNA in posttranscriptional gene silencing in plants. Science 1999 ; 286 : 950-2.
74. Bartel B. MicroRNAs directing siRNA biogenesis. Nat Struct Mol Biol 2005 ; 12 : 569-71.
75. Brennecke J, Cohen SM. Towards a complete description of the microRNA complement of animal genomes. Genome Biol 2003 ; 4 : 228.
76. Lecellier CH, et al. A cellular microRNA mediates antiviral defense in human cells. Science 2005 ; 308 : 557-60.
77. Baulcombe DC, Molnar A. Crystal structure of p19 : a universal suppressor of RNA silencing. Trends Biochem Sci 2004 ; 29 : 279-81.
78. Delgadillo MO, et al. Human influenza virus NS1 protein enhances viral pathogenicity and acts as an RNA silencing suppressor in plants. J Gen Virol 2004 ; 85 : 993-9.
79. Bucher E, et al. The influenza A virus NS1 protein binds small interfering RNAs and suppresses RNA silencing in plants. J Gen Virol 2004 ; 85 : 983-91.
80. Li WX, et al. Interferon antagonist proteins of influenza and vaccinia viruses are suppressors of RNA silencing. Proc Natl Acad Sci USA 2004 ; 101 : 1350-5.
81. Cullen BR. Is RNA interference involved in intrinsic antiviral immunity in mammals? Nat Immunol 2006 ; 7 : 563-7.
82. Schroder AR, et al. HIV-1 integration in the human genome favors active genes and local hotspots. Cell 2002 ; 110 : 521-9.
83. Wu X, et al. Transcription start regions in the human genome are favored targets for MLV integration. Science 2003 ; 300 : 1749-51.
84. Leclercq I, et al. Basis of HTLV type 1 target site selection. AIDS Res Hum Retroviruses 2000 ; 16 : 1653-9.
85. Bushman F, et al. Genome-wide analysis of retroviral DNA integration. Nat Rev Microbiol 2005 ; 3 : 848-58.
86. Lehmann-Che J. Insights into integration site selection : application for vector design. In : Thebault S, ed. Progress in virus research. Nova Science Publishers, 2005.
87. Mitchell RS, et al. Retroviral DNA integration : ASLV, HIV, and MLV show distinct target site preferences. PLoS Biol 2004 ; 2 : E234.
88. Trobridge GD, et al. Foamy virus vector integration sites in normal human cells. Proc Natl Acad Sci USA 2006 ; 103 : 1498-503.
89. Nowrouzi A, et al. Genome-wide mapping of foamy virus vector integrations into a human cell line. J Gen Virol 2006 ; 87 : 1339-47.
90. Sandmeyer S. Integration by design. Proc Natl Acad Sci USA 2003 ; 100 : 5586-8.
91. Stenbak CR, Linial ML. Role of the C terminus of foamy virus Gag in RNA packaging and Pol expression. J Virol 2004 ; 78 : 9423-30.
92. Muriaux D, et al. RNA is a structural element in retrovirus particles. Proc Natl Acad Sci USA 2001 ; 98 : 5246-51.
93. Yu F, et al. Characterization of Rous sarcoma virus Gag particles assembled in vitro. J Virol 2001 ; 75 : 2753-64.
94. Rein A. Retroviral RNA packaging : a review. Arch Virol Suppl 1994 ; 9 : 513-22.
95. Wang SW, Noonan K, Aldovini A. Nucleocapsid-RNA interactions are essential to structural stability but not to assembly of retroviruses. J Virol 2004 ; 78 : 716-23.
96. Heinkelein M, et al. Complex effects of deletions in the 5′ untranslated region of primate foamy virus on viral gene expression and RNA packaging. J Virol 2000 ; 74 : 3141-8.
97. Swanstrom R, Wills JW. Synthesis, assembly and processing of viral proteins. In : Coffin JM, ed. Retroviruses, SHHaHEV. Cold Sping Harbor Laboratory Press, 1997.
98. Heinkelein M, et al. Characterization of a cis-acting sequence in the Pol region required to transfer human foamy virus vectors. J. Virol 1998 ; 72 : 6307-14.
99. Heinkelein M, et al. Pregenomic RNA is required for efficient incorporation of pol polyprotein into foamy virus capsids. J Virol 2002 ; 76 : 10069-73.
100. Peters K, et al. RNA and protein requirements for incorporation of the Pol protein into foamy virus particles. J Virol 2005 ; 79 : 7005-13.
101. Cartellieri M, et al. Determination of the relative amounts of Gag and Pol proteins in foamy virus particles. Retrovirology 2005 ; 2 : 44.
102. Goepfert PA, et al. An endoplasmic reticulum retrieval signal partitions human foamy virus maturation to intracytoplasmic membranes. J Virol 1999 ; 73 : 7210-7.
103. Goepfert PA, et al. A sorting motif localizes the foamy virus glycoprotein to the endoplasmic reticulum. J Virol 1997 ; 71 : 778-84.
104. Kong XH, et al. The requirements and mechanism for capsid assembly and budding of bovine foamy virus. Arch Virol 2005 ; 150 : 1677-84.
105. Wilk T, et al. Specific interaction of a novel foamy virus Env leader protein with the N-terminal Gag domain. J Virol 2001 ; 75 : 7995-8007.
106. Geiselhart V, et al. Features of the Env leader protein and the N-terminal Gag domain of feline foamy virus important for virus morphogenesis. Virology 2003 ; 310 : 235-44.
107. Baldwin DN, Liniam ML. Proteolytic activity, the carboxy terminus of Gag, and the primer binding site are not required for Pol incorporation into foamy virus particles. J Virol 1999 ; 73 : 6387-93.
108. Fischer N, et al. Foamy virus particle formation. J Virol 1998 ; 72 : 1610-5.
109. Pietschmann T, et al. Foamy virus capsids require the cognate envelope protein for particle export. J Virol 1999 ; 73 : 2613-21.
110. Baldwin DN, Linial ML. The roles of Pol and Env in the assembly pathway of human foamy virus. J Virol 1998 ; 72 : 3658-65.
111. Shaw KL, et al. Foamy virus envelope glycoprotein is sufficient for particle budding and release. J Virol 2003 ; 77 : 2338-48.
112. Patton GS, et al. Identification of domains in gag important for prototypic foamy virus egress. J Virol 2005 ; 79 : 6392-9.
113. Stange A, et al. Characterization of prototype foamy virus gag late assembly domain motifs and their role in particle egress and infectivity. J Virol 2005 ; 79 : 5466-76.
114. Murray SM, et al. Expanded tissue targets for foamy virus replication with simian immunodeficiency virus-induced immunosuppression. J Virol 2006 ; 80 : 663-70.
115. Switzer WM, et al. Ancient co-speciation of simian foamy viruses and primates. Nature 2005 ; 434 : 376-80.